Having personally attended as an observer the NICE committee meeting evaluation of RECELL in Manchester I can report the single biggest issue was the lack of independent economic modelling, that would allow the NHS to recommend the use. BARDA funding has fixed this and a return to many markets with tailored economic data will be very rewarding when they get to it.
Why AVH's sale in US is better than Europe and Asia, page-9
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.98 |
Change
-0.220(5.24%) |
Mkt cap ! $219.7M | |||
| Open | High | Low | Value | Volume |
| $4.06 | $4.08 | $3.93 | $963.6K | 240.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175 | $3.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.01 | 1680 | 1 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |
